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Expression of profilin-1 (Pfn1) is downregulated in breast cancer cells, the functional significance of which is yet to be understood. To
address this question, in this study we evaluated how perturbing Pfn1 affects motility and invasion of breast cancer cells. We show
that loss of Pfn1 expression leads to enhanced motility and matrigel invasiveness of MDA-MB-231 breast cancer cells. Interestingly,
silencing Pfn1 expression is associated with downregulation of both cell–cell and cell–matrix adhesions with concomitant increase in
motility and dramatic scattering of normal human mammary epithelial cells. Thus, these data for the first time suggest that loss of Pfn1
expression may have significance in breast cancer progression. Consistent with these findings, even a moderate overexpression of
Pfn1 induces actin stress-fibres, upregulates focal adhesion, and dramatically inhibits motility and matrigel invasiveness of MDA-
MB-231 cells. Using mutants of Pfn1 that are defective in binding to either actin or proline-rich ligands, we further show that
overexpressed Pfn1 must have a functional actin-binding site to suppress cell motility. Finally, animal experiments reveal that
overexpression of Pfn1 suppresses orthotopic tumorigenicity and micro-metastasis of MDA-MB-231 cells in nude mice. These data
imply that perturbing Pfn1 could be a good molecular strategy to limit the aggressiveness of breast cancer cells.
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Cell migration, a fundamental aspect of tumour cell invasion and
metastasis, involves dynamic remodelling of actin cytoskeleton via
concerted actions of many different classes of actin-binding
proteins (ABPs). Changes in actin cytoskeleton in malignant cells
have been found to be correlated with altered expression of various
ABPs (Vandekerckhove et al, 1990; Button et al, 1995; Wang et al,
1996; Clark et al, 2000; Pawlak and Helfman, 2001). Experimental
manipulations restoring the normal expression levels of several
different types of ABPs have been successful in suppressing the
phenotype of transformed cells (Gluck et al, 1993; Tanaka et al,
1995; Nikolopoulos et al, 2000), therefore implying that deregula-
tion of ABPs directly contribute to oncogene-induced transformed
phenotype of tumour cells. In the emerging story on the role of
ABPs in cancer, profilin-1 (Pfn1 – a ubiquitously expressed
G-actin-binding protein) is found to be expressed at a significantly
low level in both human breast cancer tissue and a variety of breast
carcinoma cell lines (Janke et al, 2000), pancreatic (Gronborg et al,
2006) and hepatic (Wu et al, 2006) carcinoma cells compared to
their normal counterparts. These interesting observations appear
to suggest that loss of Pfn1 expression may have a general
relevance in cancer progression. Pfn1-overexpressing CAL51
breast cancer cells failed to form tumours when xenografted
subcutaneously in nude mice, which suggested that Pfn1 could also
be a tumour-suppressor protein (Janke et al, 2000; Wittenmayer
et al, 2004). Whether overexpression of Pfn1-elicits similar
tumour-suppressive effect at the orthotopic site is not known.
Although Pfn1 was originally discovered as an actin monomer-
sequestering protein (Karlsson et al, 1977), its cellular concentra-
tion does not appear to adequately account for the G-actin content
in cells. Since Pfn1 enhances ADP-to-ATP exchange on G-actin,
and is capable of adding ATP-bound G-actin to the barbed ends of
growing filaments, it is now mainly thought to be a promoter of
actin polymerisation (Witke, 2004). Besides actin, Pfn1 binds to
phosphoinositides (mainly phosphatidylinositol-4,5-bisphosphate
(PIP2) and phosphatidylinositol-3,4,5-triphosphate (PIP3) – Moens
and Bagatolli, 2007) and a number of proline-rich proteins ranging
from those participating in cytoskeletal to transcriptional control
in cells (Witke, 2004). Pfn1-interacting protein families that are of
particular relevance in the context of cell migration are the ones
directly involved in cytoskeletal regulation, such as vasodilator
stimulated phosphoprotein (VASP – Reinhard et al, 1995),
Wiskott-Aldrich syndrome protein (WASP; example: Neuronal or
N-WASP (Suetsugu et al, 1998), WAVE or WASP-associated
verprolin homology (Miki et al, 1998)) and Diaphanous (example:
mDia (Watanabe et al, 1997)). It has been hypothesised that these
proline-rich proteins, when activated by signals, act as scaffolds to
spatially recruit Pfn1–actin complex to the zones of active actin
remodelling during cell migration.
Because of the multitude of its ligands, Pfn1 has been implicated
in a wide range of cellular activities including proliferation,
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smigration, endocytosis, mRNA splicing and gene transcription
(Witke, 2004), which may explain why embryos null for Pfn1 or its
homologue fail to survive in higher organisms (Verheyen and
Cooley, 1994; Witke et al, 2001). A large number of pathogen-
based model studies have implied Pfn1’s function in actin-based
protrusion during cell migration (Theriot et al, 1994; Mimuro et al,
2000; Grenklo et al, 2003). A more direct evidence of Pfn1’s
importance in mammalian cell migration, particularly for its role
in cell protrusion, has been recently demonstrated in human
vascular endothelial cells by our group (Ding et al, 2006). Given
these findings, it is thus not clear why Pfn1 expression is
significantly downregulated in different types of invasive cancer
cells. This knowledge gap is partly due to lack of reports
correlating Pfn1 expression with motility and invasiveness of
tumour cells and/or their normal counterparts. We postulated that
Pfn1 is a negative regulator of mammary carcinoma aggressive-
ness. Related to this postulate, we first investigated how loss of
Pfn1 expression affects the motility of breast cancer cells and
normal human mammary epithelial cells (HMEC). We then studied
the effects of overexpression of either functional or ligand-binding
deficient mutants of Pfn1 on breast cancer cell motility. To better
relate to the process of tumour cell invasion in vivo, we next
investigated whether perturbing Pfn1 expression modulates the
intrinsic invasiveness of breast cancer cells. Finally, we evaluated
the effect of Pfn1 overexpression on breast cancer cells in vivo in
an orthotopic xenograft model system.
MATERIALS AND METHODS
Antibodies and reagents
Polyclonal Pfn1 and N-WASP antibodies were generous gifts of Drs
Sally Zigmond (University of Pennsylvania, Philadelphia, PA,
USA) and Dr Hideki Yamaguchi (Albert Einstein College of
Medicine, NY, USA). Monoclonal VASP, vimentin, E-cadherin,
keratin-18 and GFP antibodies were obtained from Pharmingen
(San Diego, CA, USA). Polyclonal GFP antibody was purchased
from the same source. Monoclonal GAPDH antibody was obtained
from Abd-serotec (Raleigh, NC, USA). Polyclonal mDia antibody is
from Abcam (Cambridge, MA, USA). Monoclonal actin and
vinculin antibodies are from Chemicon (Temecula, CA, USA)
and Sigma (St Louis, MO, USA), respectively. Collagen type I is a
product of BD Biosciences (Bedford, MA, USA). All other cell
culture reagents are products of Invitrogen (Carlsbad, CA, USA).
Generation of Pfn1 constructs
The construction of GFP-Pfn1 expression vector has been
previously described (Roy and Jacobson, 2004). We used PCR-
based site directed mutagenesis to create H119E and H133S
mutants of GFP-Pfn1. The forward and reverse PCR primers used
for creating the H133S mutant were 50-GTTATGAAATGGCCTC
TAGCCTGCGGCGTTCCCA-30 and 50-TGGGAACGC CGCAGGCT
AGAGGCCATTTCATAA-30, respectively. The forward and reverse
PCR primers for generating the H119E mutant were 50-GCAAAGA
AGGTGTCGAAGGTGGTTTG-30 and 50-CAAACCACCTTCGACAC
CTTCTTTGG-30, respectively.
Cell culture and transfection
HEK293 cells were cultured in DMEM-F12 media supplemented
with 10% fetal bovine serum (FBS) and antibiotics. MDA-MB-231
breast cancer cells were cultured in EMEM media supplemented
with 10% FBS, sodium pyruvate and antibiotics. Human mammary
epithelial cells (source: Cambrex, Walkersville, MD, USA) were
cultured in a complete growth media supplied by the manufac-
turer. Plasmid transfection of cells was perfomed using lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s protocol.
Stable clones of MDA-MB-231 cells were selected and maintained
using the regular growth media containing 1mgml
 1 G418. In
gene silencing experiments, cells were transfected with either a
control siRNA or a custom-designed Pfn1-siRNA as previously
described (Ding et al, 2006).
Protein extraction and immunoprecipitation
Total cell lysate was prepared by extracting cells with modified
RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1% NP-40,
0.25% sodium deoxycholate, 0.1% SDS, 2mM EDTA, 50mM NaF,
1m M sodium pervanadate and protease inhibitors). For immuno-
precipitation, 1000mg of lysate (extracted using a similar lysis
buffer without SDS) was first precleared with 30ml of protein-G/
protein A-conjugated agarose beads. Precleared lysate was
incubated with 4mg of polyclonal GFP antibody for 4h and then
with 75ml of the same beads for an additional hour. Immuno-
precipitated protein sample was washed three times with the lysis
buffer, resuspended in 30mlo f2   sample buffer and run on an
SDS–PAGE. For immunoblotting, the antibodies were used at the
following concentrations: Pfn1 (1:500), VASP (1:500), GAPDH
(1:3000), vimentin (1:1000), actin (1:1000), N-WASP (1:1000),
mDia1 (1:2500), vinculin (1:1000) and GFP (1:2000), keratin-18
(1:1000).
Polyproline binding assay
Poly-L-proline (PLP, source: Sigma) was conjugated to cyanogens
bromide-activated agarose beads as recommended by the manu-
facturer. Approximately, 150–200mg of cell lysates were incubated
with 30ml of PLP beads on a rotating wheel for 1h at 41C. Poly-L-
proline beads were pelleted by centrifugation, washed with the
lysis buffer 3–4 times and resuspended in 2 sample buffer for
further immunoblot analyses.
Biochemical fractionation
Cells were first washed with ice-cold F-actin stabilisation buffer
(50mM PIPES-pH 6.9, 50mM NaCl, 5% glycerol, 5mM EGTA, 5mM
MgCl2,1m M ATP, 1mM DTT, 0.1% b-mercaptoethanol) and then
extracted with buffer A (F-Actin stabilisation buffer supplemented
with 0.5% Triton-X plus protease inhibitors) for 10min to remove
soluble proteins (contain G-actin). Culture plate was washed with
buffer A and was further extracted with warm 1 sample buffer to
obtain the Triton-insoluble fraction.
Immunostaining
For vinculin immunostaining, cells were washed three times with
PBS, fixed with 3.7% formaldehyde for 15min, permeablised with
0.5% Triton X-100 for 5min and then blocked with 10% goat-
serum for 30min. After incubating with the primary antibody at
1:100 dilution for 1h at room temperature, cells were washed five
times with PBS and then incubated with a fluorophore-conjugated
secondary antibody for an additional hour at room temperature.
Stained cells were washed five times with PBS before mounting on
slides for microscopy. For E-cadherin immunostaining, we used a
similar procedure except in this case cells were fixed in ice-cold
methanol for 10min and blocked with 1% BSA for 45min, before
staining with the primary antibody at a 1:50 dilution. Phalloidin
staining was performed as previously described (Roy and
Jacobson, 2004).
Cell motility and invasion assays
Wound-healing experiments were performed as previously de-
scribed (Ding et al., 2006). Width of the wound for any field of
observation was measured at 3–4 different locations. Wound
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sclosure was quantified by the change in wound width and averaged
for three fields of observation per well from a 3–4 replicate set of
samples for any experimental condition. Transwell migration
experiments were performed as previously described (Roy
and Jacobson, 2004) with slight modifications. Briefly, 50000
serum-starved cells were seeded in triplicates in the upper
chamber of the transwells (filters coated on both sides with
10mgml
 1 collagen) and allowed to migrate for a certain time
(equal to 3 and 6h for MDA-MB-231 cells and HMEC, respectively)
towards the bottom chamber containing either serum-free
(control wells) or serum-supplemented media. Nuclei of transmi-
grated cells (stained with Hoechst) were scored at 4–5 random
fields of observation. To measure true chemotaxis, the average
number of transmigrated cells in the control wells (represents
random migration) was subtracted from the same achieved
under the serum gradient. For single-cell motility assays, time-
lapse imaging of cells was performed simultaneously at three
random fields and at an interval of 60–90s for a total duration of
90min. The acquired images were analysed using the Metamorph
software.
For invasion experiments, commercially available transwell
chambers that are precoated with matrigel (Source: BD Bio-
sciences, Bedford, MA, USA) were used. The invasion assay was
performed according to the manufacturer’s instructions where
25000 cells were plated in 3–4 replicates in either invasion or
control chambers (lacks matrigel layer) under a chemotactic
gradient of serum. After 24h, cells that have either trans-migrated
(in control chambers) or invaded and reached the bottom of the
filters were scored at five random fields of observation, and
averaged for the replicate wells. Percentage of invading cells for
any treatment group was calculated by dividing the average
number of invading cells by that of trans-migrated cells. All
motility and invasion experiments for gene silencing-based studies
were carried out either 72 (for MDA-MB-231 cells) or 96 (for
HMEC)h after siRNA transfection.
Cell-adhesion assay
In total, 20000 HMEC were non-enzymatically dissociated, stained
with 5mM calcein AM (Invitrogen, Carlsbad, CA, USA) and then
plated in triplicate on a dense monolayer of unlabelled cells in a
96-well plate. After allowing 30min for cell–cell attachment, the
culture plate was centrifuged at 200g force for 2min and then
washed gently with PBS twice to remove the unattached cells. Cell–
cell adhesion strength was scored by recording the fluorescence
intensity of labelled cells that remained attached in the well
using a plate fluorometer. Absolute fluorescence readings were
background subtracted, averaged for the replicate set of samples
from a total of four independent experiments for statistical
comparison.
Animal studies
Two million cells, suspended in 200ml of sterile PBS, were
orthotopically injected into the right inguinal mammary fat pad
of 4-week old nude female mice. After killing the animals at either
5–6- or 8-week time points after injection, tissues from lung, liver
and spleen were harvested for histological staining. These
experiments were performed in compliance with an approved
protocol by the Institutional Animal Care Committee of the
University of Pittsburgh.
Statistics
All experimental data were analysed by ANOVA followed by
Dunnett’s post hoc test within a 95% significance level.
RESULTS
Loss of Pfn1 expression enhances motility of breast cancer
and normal HMEC
Similar to previous observation of Pfn1 downregulation in human
breast cancer tissue and a wide range of other breast carcinoma
cell lines (Janke et al, 2000), we observed that MDA-MB-231, our
model breast cancer cell line, also expresses significantly less Pfn1
compared to normal HMEC (Figure 1A). Because of a general
theme of Pfn1 downregulation in many different breast cancer cell
lines, we specifically hypothesised that downregulation of Pfn1
expression confers increasing aggressiveness to both normal
HMEC and breast cancer cells. To test this hypothesis, we adopted
gene-silencing approach where we transiently transfected MDA-
MB-231 breast cancer cells and HMEC with either a control or
Pfn1-specific siRNA, and examined the changes in cell motility.
Figure 1B shows a Pfn1 immunoblot of MDA-MB-231 cell lysates
confirming near 100% suppression of Pfn1 expression achieved
within 72h after siRNA transfection. Since Pfn1 can function as a
promoter of actin polymerisation, particularly during cell protru-
sion, we asked whether loss of Pfn1 expression affects the actin
cytoskeleton and morphology of MDA-MB-231 cells. Biochemical
fractionation experiments revealed that cells lacking Pfn1 have
significantly less actin in the Triton-insoluble fraction when
compared to the same for control siRNA-treated cells, therefore
meaning that Pfn1-depletion results in reduced F-actin content in
MDA-MB-231 cells (Figure 1C). The overall actin level in MDA-
MB-231 cells also appeared to be slightly reduced when Pfn1
expression was silenced (Figure 1C). We next performed
phalloidin staining of transfected cells, which showed that
although cells lacking Pfn1 develop spatial asymmetry marked
by preferential protrusion at one end, the overall flare of
lamellipodial protrusion and F-actin staining near the leading
edge are markedly reduced with respect to the control cells
(Figure 1D). The effect of silencing Pfn1 expression on cell motility
was next analysed using a wound-healing assay, the results of
which are depicted in Figure 1E–F. Data analyses revealed that
suppressing Pfn1 expression leads to a significant 40% increase in
motility of MDA-MB-231 cells (Figure 1F). These results were
further confirmed by similar finding from transwell migration
experiments (data not shown).
Similar to our finding in MDA-MB-231 cells, silencing Pfn1
expression in normal HMEC was found to decrease the cellular
F-actin content by 35% (data not shown) and increase their
chemotactic migration by a significant 51% in a transwell-based
assay (Figure 1G – the immunoblots in the inset confirm siRNA-
mediated suppression of Pfn1 expression in HMEC). Transwell
data were further verified by similar observation from wound-
healing experiments with HMEC (data not shown). Increased
motility associated with loss of Pfn1 expression is also reflected by
dramatic scattering (indicative of greater disseminative capacity)
of Pfn1-siRNA-treated HMEC compared to control cells (displays
typical clustered morphology) in subconfluent culture conditions
(Figure 1H).
Some of the hallmark changes that facilitate epithelial cell
dissemination and migration during cancer progression are
downregulation of both cadherin-based cell–cell and cell–matrix
adhesions. Because of increased scattering of Pfn1-siRNA-treated
cells in culture, we asked whether loss of Pfn1 expression is
associated with altered adhesive properties of HMEC. Our
immunostaining data showed that Pfn1-depleted HMEC have
much less E-cadherin distribution at the cell–cell junctions
compared to control siRNA-treated cells (Figure 2A). To further
determine whether loss of Pfn1 expression actually inhibits HMEC
to form cell–cell adhesion, we performed a functional cell-
adhesion assay. Even within the first 30min of cell attachment
phase, there was a significant 46% reduction in the intercellular
Profilin-1 in breast cancer cell motility and invasion
L Zou et al
1363
British Journal of Cancer (2007) 97(10), 1361–1371 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sadhesion strength of HMEC when Pfn1 expression was suppressed
(Figure 2B). Although centrifugation-based cell–cell adhesion
assay as adopted in the present study is widely used, it suffers from
a potential drawback that detachment of unlabelled cells from the
underlying substratum, if occurs in response to centrifugal force,
can confound the results. However, we did not see any evidence of
disruption of monolayer formed by unlabelled cells in response to
the applied centrifugal force for either of the treatment groups
(data not shown), and thus we feel confident that our experimental
readouts truly represent cell–cell adhesion strength. Also, since
this assay scores the number of cells attached to a monolayer of
cells as opposed to measuring the actual force, we preferred to
obtain our experimental readout shortly after cell-seeding rather
than at later time points where differences in the rate of cell
proliferation between the two transfection conditions may
confound the results. However, from a dramatic scattering of
Pfn1-depleted HMEC in culture as shown in Figure 1H, a 46%
reduction in experimental readout from the functional assay is
most likely a gross underestimate of the actual downregulation of
cell–cell adhesion induced by loss of Pfn1 expression. Next, to
assess the effect of silencing Pfn1 expression on cell–matrix
adhesions, we performed vinculin immunostaining of transfected
cells which showed that HMEC lacking Pfn1 have much less
pronounced focal adhesions (FAs) compared to control siRNA-
treated cells (Figure 2C). A histogram in Figure 2D illustrates the
significant difference in the FA size between the control (average
size: 425±237 square pixels; n¼775 FAs from 48 cells) and Pfn1-
siRNA-treated cells (137±69; n¼788 FAs from 51 cells). Taken
together, these data demonstrate that loss of Pfn1 expression
primes HMEC and breast cancer cells to a more migratory
phenotype, and thus support our overall postulate.
Overexpression of Pfn1 alters morphology and
dissemination of MDA-MB-231 cells
As a complementary approach to gene silencing, we next adopted
overexpression of GFP-Pfn1 in MDA-MB-231 cells as previously
accomplished in BT474 breast cancer cells (Roy and Jacobson,
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Figure 1 Silencing Pfn1 expression increases MDA-MB-231 and HMEC motility. (A) Immunoblot of total cell lysates (20mg loaded in each line) shows
that MDA-MB-231 cells express significantly less Pfn1 compared to HMEC. (B) Immunoblot of MDA-MB-231 cell lysates confirms siRNA-mediated
suppression of Pfn1 expression (the GAPDH blot serves as the loading control). (C) Immunoblot shows that Triton-insoluble fraction of MDA-MB-231 cell
lysates has significantly less actin when Pfn1 expression is silenced (the vimentin blot serves as the loading control). Total actin expression is also slightly
reduced in MDA-MB-231 cells after silencing Pfn1 expression (the keratin-18 blot serves as the loading control). (D) Phalloidin staining shows reduced flare
of protrusion in Pfn1-depleted MDA-MB-231 cells (bar – 30mm). (E–F) Representative images of wound-healing experiments (E; bar – 200mm) and a bar
graph (F – summarised from four experiments) illustrate the effect of silencing Pfn1 expression on MDA-MB-231 cell motility. (G) A bar graph summarises
the results of two independent experiments that examined the effect of silencing Pfn1 on HMEC chemotaxis in a transwell-based assay (Pfn1 immunoblot in
the inset demonstrates siRNA-mediated suppression of Pfn1 expression in HMEC with VASP blot serving as the loading control). (H) Phase-contrast images
show dramatic scattering of Pfn1-depleted HMEC in culture (bar – 200mm).
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s2004). Several different point mutants of Pfn1 that are defective in
binding specifically to actin (H119E, R74E) and polyproline
(H133S, W3A, W3N) have been reported in the literature
(Bjorkegren-Sjogren et al, 1997; Suetsugu et al, 1999; Lambrechts
et al, 2006). To selectively modulate Pfn1’s interactions with actin
and proline-rich proteins, we adopted overexpression of H119E
and H133S mutants of Pfn1 (also GFP-fused), respectively. To
initially confirm that fusing GFP to Pfn1 mutants still preserves
their selective loss of functions, we transiently expressed each of
these Pfn1 constructs in HEK293 cells. Co-immunoprecipitation
(Figure 3A i–ii) and polyproline pull-down assays (Figure 3A-iii)
confirmed loss of actin and polyproline binding specifically for
GFP-Pfn1-H119E and GFP-Pfn1-H133S, respectively.
We next engineered MDA-MB-231 cells to stably express either
GFP (control) or different Pfn1 constructs as indicated above.
GFP-immunoblot of cell lysates showed comparable expression
levels of different forms of exogenous Pfn1 in MDA-MB-231
sublines (Figure 3B). There was no appreciable change in
endogenous Pfn1 expression between the various cell lines
(Figure 3B). Quantitative immunoblots using known amounts of
recombinant Pfn1 and GFP as standards showed that the
expression level of GFP-Pfn1 or its mutants is about 60% of that
of endogenous Pfn1 (data not shown).
Morphological examination showed that GFP-Pfn1-expressing
cells tend to form significant clusters in normal culture
(Figure 3C), and are also much more spread-out compared to
other engineered MDA-MB-231 cell lines (Figure 3D). Since neither
of the mutant cell lines exhibits increased spreading, it implies that
interactions with both actin and proline-rich ligands are necessary
for Pfn1-induced enhancement in cell spreading. Although
clustered morphology is a typical epithelioid feature, our
immunoblot data showed that Pfn1-overexpressing cells do not
re-express epithelial marker E-cadherin (Figure 3E). Therefore,
Pfn1 overexpression does not appear to induce complete epithelial
reversion of MDA-MB-231 cells, and clustered morphology of
Pfn1-overexpressing cells is likely to be due to their decreased
ability to disseminate in culture.
Pfn1 overexpression reorganises actin cytoskeleton and
upregulates FAs in MDA-MB-231 cells
Previous studies showed diverse cellular effects of overexpressed
or microinjected Pfn1, where in some cases an increase in the
overall F-actin content was noticed (Finkel et al, 1994) and in
others depolymerisation of existing actin filaments occurred (as
could be expected from its G-actin-sequestering property –
Balasubramanian et al, 1994). This demonstrates the complexity
and cell-type specificity of Pfn1’s action on actin cytoskeleton. In
our case, phalloidin-staining showed that both parental (data not
shown) and GFP-expressing MDA-MB-231 cells typically exhibit
cortical F-actin staining with a stronger bias at the leading edge
(Figure 4A). A distinguishing feature of GFP-Pfn1 expressers is the
formation of long actin cables that are organised as peripheral
F-actin belt (arrow) as well as in a stress-fibre-like fashion
(arrowhead – Figure 4A). Immunoblot analyses of total cell lysates
confirmed that there are no marked differences in the expression
levels of either actin or other known major promoters of actin
polymerisation, such as VASP, N-WASP and mDia1, between these
two cell lines (Figure 4B). These data therefore demonstrate that
even a very moderate level of Pfn1 overexpression can cause a
marked change in the cytoskeletal organisation of MDA-MB-231
cells, and it is most likely via direct modulation of actin
polymerisation and/or bundling of actin filaments. Furthermore,
we observed that Pfn1 overexpression significantly increases the
number and size of vinculin-positive FA plaques without
appreciably affecting the total expression level of vinculin (Figures
4C–D). These data demonstrate that Pfn1 overexpression upre-
gulates FAs in MDA-MB-231 cells.
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Figure 2 Loss of Pfn1 expression downregulates cell–cell and cell–cell matrix adhesions in HMEC. (A) Immunostaining shows reduced junctional
distribution of E-cadherin in Pfn1-depleted HMEC compared to the control-siRNA-treated cells (bar – 50mm). (B) A bar graph illustrating the inhibitory
effect of silencing Pfn1 expression on cell–cell adhesion (N¼4 experiments). (C) Vinculin immunostaining shows less pronounced focal adhesions in Pfn1-
depleted HMEC (bar – 24mm). (D) A histogram reveals the difference in the distribution of focal adhesion size between control and Pfn1-siRNA-treated
HMEC.
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suppress MDA-MB-231 cell motility
To determine the effect of overexpression of Pfn1 in cell motility,
we first performed transwell migration experiments which showed
that overexpression of GFP-Pfn1 suppresses chemotaxis of MDA-
MB-231 cells by nearly 80% (Figure 5A). Since the ability of cells to
migrate through the pores in a transwell filter may be affected by
their size (a potential issue for GFP-Pfn1-expressing cells), we also
performed single-cell motility assay to confirm our transwell
results. These experiments showed that GFP-expressers are able to
randomly migrate with significant cell translocation (Figure 5B).
By contrast, GFP-Pfn1-expressing cells fail to generate spatial
asymmetry (almost maintains the same shape) and translocate
during the course of observation (Figure 5B). A histogram in
Figure 5C summarises the time-lapse data from two independent
experiments which shows that the net distance translocated by
GFP-expressing cells (41±23.3mm) is almost six-fold higher than
that calculated for GFP-Pfn1 expressers (7±5.7mm).
We next assessed the effect of overexpression of H119E and
H133S mutants of Pfn1 on MDA-MB-231 cell motility. Data from
transwell experiments showed that overexpression of GFP-Pfn1-
H133S suppresses chemotaxis of MDA-MB-231 cells by 55%,
whereas no significant difference in chemotaxis is observed
between GFP and GFP-Pfn1-H119E-expressing cells (Figure 6A).
Further confirmation of these results came from wound-healing
experiments which showed a similar 40% inhibition in motility
induced by GFP-Pfn1-H133S overexpression with GFP-Pfn1-
H119E expression having no effect at all (Figures 6B, C). These
results were verified with two different clones of each of our
mutant cell lines and thus our findings are not clone-specific
effects. Overall, these data thus demonstrate that a functional
actin-binding site is required for overexpressed Pfn1 to suppress
MDA-MB-231 cell motility. Although overexpression of both
functional Pfn1 and its H133S mutant suppress cell migration,
these two cell lines behave very different as revealed from time-
lapse imaging data. In contrast to GFP-Pfn1 expressers, cells
expressing GFP-Pfn1-H133S are highly dynamic, generate multiple
and randomly directed protrusions throughout the period of
observation (Figure 6D). We found that net distance translocated
by GFP-Pfn1-H133S expressers (19.7±16.1mm; n¼44 cells pooled
from two experiments) is still almost two-fold less than the
corresponding value for GFP-expressing cells; this finding is in
good agreement with our previous transwell and wound-healing
data. Since one of the important functions of Pfn1 is to regulate
actin polymerisation during cell protrusion, we next compared the
lamellipodial dynamics of GFP, GFP-Pfn1, GFP-Pfn1-H133S
expressers from their kymographs in order to obtain further
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Figure 3 Overexpression of Pfn1 and its functional mutants. (A) Immunoprecipitated GFP-Pfn1 and its mutants (H119E, H133S) from HEK293 lysates
probed with actin-antibody shows loss of actin co-precipitation with GFP-Pfn1-H119E (i). Reprobing the same blot with GFP antibody shows equal loading
of immunoprecipitated samples (ii). PLP pull-down of HEK293 lysates immunoblotted with GFP antibody shows loss of polyproline binding of GFP-Pfn1-
H133S (iii). (B) GFP-immunoblot of lysates from MDA-MB-231 clones shows comparable levels of exogenous Pfn1 expression (upper blot). Reprobing the
blot with Pfn1 antibody shows similar levels of endogenous Pfn1 expression between the various cell lines (lower blot). (C)  10 phase-contrast images
show clustering of GFP-Pfn1-expressing MDA-MB-231 cells (bar – 100mm). (D)  20 phase-contrast images show dramatically increased spreading for
GFP-Pfn1-expressing cells compared to the other cell lines (bar – 50mm). (E) Immunoblot of cell lysates shows no evidence of E-cadherin expression in any
of the engineered MDA-MB-231 cell lines (HMEC lysate in lane 1 serves as a positive control for E-cadherin blot).
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sinsight on Pfn1-induced change in cell motility. As shown in
Figure 6E, GFP-expressing cells, in general, tend to maintain
relatively persistent protrusion as indicated by a steady positive
slope of the kymograph. By contrast, GFP-Pfn1 expressers display
nearly flat kymographs with minor oscillations of cell periphery
thus indicating suppressed lamellipodial activity. Interestingly,
GFP-Pfn1-H133S expressers show prominent protrusive activity;
however, these protrusions often undergo rapid retractions
(indicated by a negative slope of the kymograph), and are hence
much less stable. Overall, these data demonstrate that perturbing
Pfn1 alters the lamellipodial dynamics of MDA-MB-231 cells.
Pfn1 is a negative regulator of the invasiveness of
MDA-MB-231 cells
To better mimic tumour cell invasion through ECM as occurs
in vivo, we next compared matrigel invasiveness of GFP- and
GFP-expressing MDA-MB-231 cells in response to a chemotactic
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dramatically suppresses the matrigel invasiveness of MDA-
MB-231 cells by nearly four-fold (Figure 7A). Even though these
invasion experiments were carried out in a transwell-based
chamber where the pore size could be a potential issue for larger
GFP-Pfn1-expressing cells, our finding is valid for two reasons.
First, we normalised the invasion readout by the number of
transmigrating cells that was scored in the control chamber.
Second, there was absolutely no difference in the number of
transmigrating cells between the two groups at the 24-h time point
of evaluation (long enough to allow all of the seeded cells to
transmigrate). Consistent with our overexpression data, we found
that cell invasiveness increases dramatically by nearly three-fold
when Pfn1 expression is suppressed (Figure 7B). Overall, these
data prove that Pfn1 negatively regulates the intrinsic invasiveness
of MDA-MB-231 cells.
Pfn1 overexpression limits orthotopic tumorigenicity and
metastasis of MDA-MB-231 cells
The real measure of tumour invasiveness for dissemination is the
ability to form metastases in animals from an orthotopic tumour
site. In vivo effect of Pfn1 overexpression on mammary tumour
cells has been examined for only one cell line (CAL51) so far where
suppression of tumorigenicity was observed (Janke et al, 2000;
Wittenmayer et al, 2004). However, these studies were performed
in a non-orthotopic model system. Since microenvironment has a
critical influence on tumour progression, we extended our line of
inquiry to MDA-MB-231 cells in an orthotopic xenograft model
system where we injected either GFP (control) or GFP-Pfn1-
expressing cells into the inguinal mammary fat pad of nude mice.
The GFP-expressing cells formed visible tumours as expected;
however, tumour formation was completely suppressed in mice
injected with GFP-Pfn1-expressing cells (Figure 7C). The tumour
burden data at the time of killing is summarised in a tabular form
in panel D. Histology of lungs harvested from animals injected
with GFP-expressing cells revealed significant micro-metastasis
when evaluated at the 8-week time point, whereas the same for
animals bearing GFP-Pfn1 expressers appeared completely normal
(Figure 7E). Taken together, these data demonstrate that Pfn1
overexpression suppresses orthotopic tumorigenicity and micro-
metastasis of breast cancer cells.
DISCUSSION
While it has long been known that Pfn1 modulates the actin
cytoskeleton, its overall regulatory role was not well defined. Since
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for cell migration, it is not at all clear why Pfn1 expression is
downregulated in various forms of invasive cancer cells. In the
present study, we evaluate for the first time how perturbing Pfn1
affects the motility and invasiveness of breast cancer cells as well as
their normal counterparts. Several novel findings are reported in
this study. First, we demonstrate that near complete loss of Pfn1
expression actually confers increased motility and invasiveness to
breast cancer cells. Conversely, overexpression of Pfn1 suppresses
motility and invasiveness of breast cancer cells. Taken together,
these observations suggest for the first time that Pfn1 is a negative
regulator of mammary carcinoma aggressiveness. Second, we find
that silencing Pfn1 expression in HMEC leads to downregulation of
both cell–cell and cell–matrix adhesions, increased motility and
dramatic scattering. Since these cellular changes are precursor to
tumour cell dissemination in vivo, our findings for the first time
provide a possible insight on why Pfn1 expression has to be
downregulated in breast cancer cells. Third, the present study is
the first demonstration of the in vivo effect of Pfn1 overexpression
on breast cancer cells in an orthotopic setting. Our finding that
Pfn1 overexpression suppresses orthotopic tumorigenicity of
MDA-MB-231 cells reproduces previous results reported for
another breast cancer cell line in subcutaneous xenograft models
(Janke et al, 2000; Wittenmayer et al, 2004), and thus provides a
further supportive evidence for the tumour-suppressive property
of Pfn1 in breast cancer.
Gain of motility-related function after Pfn1 depletion has been
unprecedented in the literature. Although further mechanistic
studies are needed to elucidate why Pfn1 depletion increases
motility in breast cancer cells, yet dramatically inhibits motility of
other cell types, such as vascular endothelial cells (Ding et al,
2006), certain speculations may be appropriate. First, whether Pfn1
would inhibit or facilitate actin polymerisation depends on its
concentration relative to G-actin and uncapped barbed ends of
actin filaments. These parameters are also regulated by other
ABPs, the cellular concentrations of which vary between different
cell types. Because of this complex nature of its action on actin
cytoskeleton, Pfn1 can have either concentration and/or cell-type
dependent effect on cell motility. Given that the concentration of
residual Pfn1 after gene silencing could also vary between different
cell systems, a direct comparison can sometimes be difficult.
Second, disruption of actin filaments is a known feature
following oncogene-induced cell transformation (Pawlak and
Helfman, 2001). Clearly, literature has documented evidence of
elevated expression of thymosin b4 (a G-actin-sequestering protein
that inhibits actin polymerisation) and loss of tropomyosin (an
F-actin-stabilizing protein) correlating with increased aggressive-
ness of carcinoma cells (Franzen et al, 1996; Kobayashi et al, 2002;
Wang et al, 2004). In fast migrating tumour cells, a moderate
decrease in cellular F-actin level can potentially enhance cell
motility by either increasing the availability of G-actin for actin-
treadmilling, and/or decreasing the overall rigidity of cell cortex
(enhances membrane deformability). Thus, it is conceivable that
by lowering the overall F-actin content in MDA-MB-231 cells, Pfn1
depletion may create a similar cytoskeletal background and favour
cell motility provided (1) other F-actin-dependent processes that
are otherwise critical for normal cell motility, such as contractility,
becomes less important, and (2) Pfn1 becomes dispensable in the
case of tumour cells. In general, highly invasive tumour cells like
MDA-MB-231 are weakly adherent in nature and thus, contractility
may be of much lesser significance in the context of motility of
these cells when compared to some of the more strongly adherent
cell types, such as vascular endothelial cells. A noteworthy point
here is that in our previous study we observed a dramatic decrease
in actin stress-fibres and FAs (the molecular machineries for
generating cell contractility) in vascular endothelial cells after
silencing Pfn1, which could partly account for their translocation
defect (Ding et al, 2006). Among its diverse functions, Pfn1 has
been most heavily implicated in actin-based cell protrusion. We
previously found that vascular endothelial cells lacking Pfn1 are
drastically impaired in generating polarised protrusion (Ding et al,
2006). In the case of MDA-MB-231 cells, although we noticed a
somewhat decrease in the overall flare of protrusion after Pfn1
depletion, polarised protrusion at the leading edge was still
evident. It was previously implied that Pfn1 facilitates, but is not
absolutely critical for the canonical WASP-Arp2/3-mediated, actin-
based protrusions in migrating cells (Loisel et al, 1999). Since
WASP-family proteins, Arp-2/3 as well as their upstream
regulators (Rac1, Cdc42) are known to be overexpressed in several
invasive cancers including breast cancer (Sahai, 2005), protrusion
of tumour cells may be much less sensitive to loss of Pfn1
expression compared to vascular endothelial cells. Also, suppres-
sion of certain protrusions, which are unproductive for forward
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Figure 7 Perturbing Pfn1 overexpression alters matrigel invasiveness,
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smovement, such as those arising at the lateral edge of the cell, leads
to better spatial asymmetry of cells (a key requirement for
directional migration). Thus, it is possible that by lowering the
overall flare of protrusion, depletion of Pfn1 may actually facilitate
this process and enhance directional motility. This is not
unreasonable since we observed exactly opposite phenomena in
the case of Pfn1-overexpressing cells which display aberrant
protrusions in all directions, fail to generate spontaneous spatial
asymmetry and are significantly impaired in translocation (also
reproduces our previous finding in BT474 cells; Roy and Jacobson,
2004). Excessive lamellipodial protrusion observed in these cells
could be a combined result of (1) Pfn1-induced stimulation of
actin polymerisation at the leading edge, (2) better stabilisation of
protrusions because of upregulated FAs and (3) a possible defect in
cell retraction due to increased adhesion.
Another interesting and novel finding is that between the two
Pfn1 mutants, overexpression of only poly-proline binding-
deficient mutant (has functional actin binding) suppresses MDA-
MB-231 cell motility. Since we showed that loss of Pfn1 expression
actually enhances motility, our findings should not be interpreted
as that Pfn1’s interaction with proline-rich ligands is required for
MDA-MB-231 cell motility. Our data rather suggest that actin
binding is necessary for Pfn1-induced suppression of breast cancer
cell motility. Because of differences in both morphology and
behaviour in time-lapse assays between GFP-Pfn1 and GFP-Pfn1-
H133S expressers, it appears that there might be some unique
differences in the underlying mechanisms of inhibition of cell
motility induced by these two constructs. Multiple and randomly
directed protrusion observed in GFP-Pfn1-H133S expressers
partially resonates with a recent finding that disrupting poly-
proline interaction of Pfn1 promotes neurite elongation in PC12
cells (Lambrechts et al, 2006). Randomness of protrusions
(impedes motility in one particular direction) could be the one
of the main reasons why directional motility is inhibited by the
H133S construct.
Although our matrigel invasion data successfully demonstrate
that Pfn1 is a negative regulator of the intrinsic invasiveness MDA-
MB-231 breast cancer cells, because of heterogeneity of tumour
cells, it will be valuable to extend these studies to both primary
cancer cells and other invasive/noninvasive breast cancer cell lines
with different endogenous levels of Pfn1. Importantly, we will have
to address key mechanistic questions such as whether perturbing
Pfn1 affects the secretion of matrix-degrading proteolytic enzymes
(an integral aspect of cell invasion) or primes tumour cells to
preferentially adapt to any special kind of motility (mesenchymal
vs ameboid) during the process of invasion. To better mimic the in
vivo process of tumour cell invasion, these future studies will need
to utilise a tumour-microenvironment model including stromal
cells (fibroblasts, macrophages) in the culture. Finally, even though
our in vivo studies show lack of micro-metastasis of Pfn1-
expressing cells, we cannot resolve whether this is due to failure
of these cells to disseminate via reduced migration and invasion
(as suggested by in vitro studies) or lack of tumour formation.
Future studies are needed to determine whether targeted over-
expression of Pfn1 in preformed tumours slows down distant
metastasis. If true, perturbing Pfn1 could prove to be a good
molecular strategy for limiting aggressiveness of breast cancer
cells.
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